CytoDyn Inc (OTCMKTS:CYDY) has been focus among investors for quite a while due to its work with regards to a coronavirus treatment and last week the company made a key announcement.

Last week, the data from the CD12 trial of its coronavirus treatment product Vyrologix was made available to CytoDyn. While it is a significant development for the company, it is important for investors to note that the results are going to be made public only after CytoDyn concludes its talks with the relevant regulatory bodies.

As part of the trial, the product had been administered to coronavirus patients and the announcement has naturally led to considerable optimism among investors.

Following the announcement, the stock gained considerable momentum and it remains to be seen if CytoDyn starts off the week with further gains. At this point, investors could do well to add the CytoDyn stock to their watch lists and keep an eye out for the publication of the results from the trial.